PDK1 and neoplasm: The selective advantage of this metabolic shift in tumor cells is still poorly understood, but a recent hypothesis postulates that enhanced glycolysis could provide a biosynthetic advantage that would better support cellular proliferation compared with OXPHOS, and that PDK1 activation, shown here to be upregulated by HPV-18 E2, may be a key activator switch (reviewed in 26).